XML 40 R40.htm IDEA: XBRL DOCUMENT v2.4.0.6
ALLIANCES AND COLLABORATIONS (Lilly) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Dec. 31, 2011
Alliances and Collaborations Statement [Line Items]          
Net sales $ 4,443 $ 5,434 $ 9,694 $ 10,445  
Other (income)/expense (18) (31) 5 (169)  
Other intangible assets - upfront, milestone and other licensing payments 4,569   4,569   3,124
ERBITUX [Member]
         
Alliances and Collaborations Statement [Line Items]          
Net sales 179 173 358 338  
Lilly [Member] | ERBITUX [Member]
         
Alliances and Collaborations Statement [Line Items]          
Net sales 179 173 358 338  
Commercialization expense reimbursements to/(from) alliance partner (6) (2) (10) (3)  
Lilly [Member] | ERBITUX [Member] | North America [Member]
         
Alliances and Collaborations Statement [Line Items]          
Distribution fee, percentage of net sales 39.00%   39.00%    
Distribution fees and royalty expense 75 71 149 140  
Lilly [Member] | ERBITUX [Member] | Japan [Member] | Commercialization Profit Sharing Income Expense [Member]
         
Alliances and Collaborations Statement [Line Items]          
Other (income)/expense (13) (6) (19) (15)  
Lilly [Member] | necitumumab [Member]
         
Alliances and Collaborations Statement [Line Items]          
Research and development reimbursements to/(from) collaboration partner 7 4 8 6  
Lilly [Member] | necitumumab [Member] | Development Costs For United States Studies [Member]
         
Alliances and Collaborations Statement [Line Items]          
Funding of development costs, percentage 55.00%   55.00%    
Lilly [Member] | necitumumab [Member] | Development Costs For Global Studies [Member]
         
Alliances and Collaborations Statement [Line Items]          
Funding of development costs, percentage 27.50%   27.50%    
Lilly [Member] | necitumumab [Member] | Development Costs For Japan Studies [Member]
         
Alliances and Collaborations Statement [Line Items]          
Funding of development costs, percentage 50.00%   50.00%    
Lilly [Member] | ERBITUX And Necitumumab [Member] | Upfront, milestone and other licensing payments [Member]
         
Alliances and Collaborations Statement [Line Items]          
Total upfront licensing and milestone payments 500   500    
Amortization expense - upfront, milestone and other licensing payments 9 9 19 19  
Other intangible assets - upfront, milestone and other licensing payments $ 230   $ 230   $ 249
Lilly and Merck KGaA [Member] | ERBITUX [Member] | Japan [Member]
         
Alliances and Collaborations Statement [Line Items]          
Percentage share of pre-tax profit/loss received from the net sales of a collaboration partner to be shared further equally with another collaboration partner. 50.00%   50.00%